ArticleFrontiers in public health2026
Research on daily medication and drug efficacy evaluation for chronic diseases based on natural language processing (NLP).
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to harness Natural Language Processing (NLP) to improve chronic disease medication management, focusing on the antihypertensive drug Lisinopril. The objectives are: (1) to develop an intelligent drug safety monitoring and personalized intervention platform integrating patient feedback; (2) to accurately identify drug side effects and analyze their associations with patient demographics; and (3) to build a personalized medication recommendation system for enhanced clinical decision-making. Methods: We used user reviews from authoritative medical databases (WebMD and Kaggle) spanning 2008-2020, forming a high-quality dataset of 345,845 samples related to Lisinopril. Data preprocessing involved redundancy removal, missing value imputation (e.g., using the KNN algorithm), and text standardization (e.g., through UMLS terminology mapping). NLP techniques included sentiment analysis and entity recognition with BERT models, topic modeling using LDA algorithms to extract key side-effect patterns (e.g., dry cough, dizziness), as well as the integration of knowledge graphs and decision trees for personalized recommendations, and the development of an interactive risk heatmap dashboard for dynamic monitoring. Results: The analysis revealed that common side effects of Lisinopril included dry cough (38%), dizziness (28%), and fatigue (22%), with nearly half of users experiencing these issues-particularly among older adults and long-term users. Sentiment analysis showed that 58% of reviews were negative, primarily due to side effects. The personalized recommendation system, tested in simulated scenarios, significantly improved medication adherence by suggesting alternatives (e.g., ARBs for cough-sensitive patients). The NLP-driven framework achieved 89.7% accuracy in sentiment classification and identified side-effect patterns 15 times faster than manual annotation. Conclusion: NLP effectively extracts insights from patient feedback, enabling rapid identification of drug efficacy and side effects. The study demonstrates the potential of NLP to support chronic disease management and precision medicine by facilitating early risk detection and personalized interventions. Future work should address subjective bias in reviews and integrate multi-source data for comprehensive assessment models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.